Explore

Trendline Trendline
Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab

Tiziana Life Sciences Reports Reduced Brain Inflammation in MSA Patients with Intranasal Foralumab
Trendline Trendline
AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics

AndzonBio2 and Cambridge Collaborate on Neuroinflammation Therapeutics
Trendline Trendline
Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development

Fosun Pharma and AriBio Sign Agreement for Alzheimer's Drug Development
Trendline Trendline
AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform

AN2 Therapeutics Advances Multiple Clinical Programs with Boron Chemistry Platform
Trendline Trendline
Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges

Biogen Advances Tau-Targeting Alzheimer's Therapy to Phase 3 Despite Mid-Stage Trial Challenges
Trendline Trendline
IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358

IMMEDIATE Therapeutics Strengthens Team to Advance Ischemic Therapy IMT-358
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Cell Therapy Program for AI-Driven Development
Trendline Trendline
Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases

Lysoway Therapeutics Begins Phase I Trial of TRPML1 Agonist for Neurodegenerative Diseases
Trendline Trendline
Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302

Coya Therapeutics Receives FDA Fast Track Designation for ALS Treatment COYA 302
Trendline Trendline
AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics

AIRNA Unveils Promising Preclinical Data on RNA-Editing Therapeutics
Trendline Trendline
AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials

AN2 Therapeutics Advances Multiple Drug Programs with New Phase 2 Trials
Trendline Trendline
Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development

Cellular Intelligence Acquires Novo Nordisk's Parkinson's Therapy to Advance Clinical Development